Can Preferentially Prescribing Angiotensin II Receptor Blockers (ARBs) over Angiotensin-Converting Enzyme Inhibitors (ACEIs) Decrease Dementia Risk and Improve Brain Health Equity?

NAM Perspect. 2022 May 9:2022:10.31478/202205c. doi: 10.31478/202205c. eCollection 2022.

Authors

Zachary A Marcum¹, Jordana B Cohen², Eric B Larson³, Jeff Williamson⁴, Adam P Bress⁵

Affiliations

¹ University of Washington.
² University of Pennsylvania.
³ Kaiser Permanente Washington Health Research Institute.
⁴ Wake Forest School of Medicine.
⁵ University of Utah.

No abstract available

Publication types

Review

Grants and funding